{"title": "Safety and efficacy of single-dose Ad26.CoV2.s vaccine against covid-19", "author": "Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky C\u00e1rdenas; Abeer Moanna; Macaya Douoguih", "url": null, "hostname": null, "description": null, "sitename": "New England Journal of Medicine", "date": "2021-06-10", "cleaned_text": "24 Views | 25 Downloads Dr. Douoguih at Janssen Vaccines and Prevention, Newtonweg 1, CP 2333 Leiden, the Netherlands, or at [mdouogui@its.jnj.com](mailto:mdouogui@its.jnj.com) We thank all the participants in this trial, the staff members at the trial locations, the members of the data and safety monitoring board, all the investigators at the clinical sites, the COV3001 study team (Richard Gorman, Carmen A. Paez, Tong, Corrina Pavetto, Teletha Gipson, Tina Tong, Fay, Kelly McQuarrie, Chimeremma Nnadi, Obiageli Dromme), Mary L. Greenacre (An Sgriobhadair) and Jill E. Kolesar and Kurt Kunz (Cello Health Communications-MedErgy) for writing and editorial assistance, funded by Janssen Global Services, with an earlier version of the manuscript. See publication for full list of authors. Supported by Janssen Research and Development, an affiliate of Janssen Vaccines and Prevention and part of the Janssen pharmaceutical companies of Johnson & Johnson, and in whole or in part by federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C, and from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI68614), the HVTN Statistics and Data Management Center (UM1 AI68635), the HVTN Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI68636), the Infectious Diseases Clinical Research Consortium Leadership Group (UM1 AI148684), and Vaccine and Therapeutic Medical Society. All rights reserved. "}